WiseGuyReports.com adds new report on “Non-Alcoholic
SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in
development, Regulatory guidelines and Market opportunity in Various
Geographies” of 65 pages with tables
and figures to its research store.
Sales of Hepatitis C drugs crossed
~$10bn in 2014 proving that treatments for liver disease could become
mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be
equally lucrative. Improved diagnosis rate and change in treatment guidelines
along with defined clinical trials endpoint are the concerns for the emerging
therapy. US FDA is expected to release guidelines for the clinical trial in
CY16 and this should accelerate the development of the drugs targeting NASH.
Complete
Report Details Available @ https://wiseguyreports.com/reports/non-alcoholic-steatohepatitis-nash-an-analysis-of-disease-prevalence-drugs-in-development-regulatory-guidelines-and-market-opportunity-in-various-geographies
.
NASH is the progressive form of
Non-Alcoholic Fatty Liver Disease – NAFLD. While NASH can reverse itself, in
many cases, the resulting liver scarring causes a patient's liver to harden and
failure to work properly. It is estimated that NASH affects 2 to 5% of the US
population. Other developed countries such as Europe and Japan also have
similar or higher incidence of NASH disease. Due to the varying physical and
metabolism traits across various geographies, development of drugs for NASH is
facing difficulty. In Japan, the prevalence of NASH is rising although the
population is not typically overweight. Countries like India and China with
bigger population and changes in lifestyles face a greater risk of NASH along
with other lifestyle diseases like Diabetes and Cardiovascular related
complexities.
As per the US Association of Liver
Disease, of those who develop NASH, ~15-25% will progress to end stage liver
disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today,
1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden
of this on US is over ~$5 billion per year. Only new treatments in NASH could
lead to a cut in this major cost burden along with improving quality of life.
Request a sample copy @ https://wiseguyreports.com/sample_request/non-alcoholic-steatohepatitis-nash-an-analysis-of-disease-prevalence-drugs-in-development-regulatory-guidelines-and-market-opportunity-in-various-geographies
.
Since a new innovation in NASH has been
enlightened, the interest in companies developing drugs for NASH has also gone
up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma’s Farnesoid X
Receptor (FXR) program comprising small molecule FXR agonists for the treatment
of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver
Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered
into an exclusive agreement for the pipeline products which are being developed
for NASH with a potential deal value of ~$450-600mn.
This report will provide detailed
analysis on NASH disease and Drugs in development in broader pharma market.
This report list all the drugs in clinical trial and their design and the
population recruited, also tells about the pathways representing possible
targets for the treatment of NASH.
Make
an enquiry before buying this Report at https://wiseguyreports.com/enquiry/non-alcoholic-steatohepatitis-nash-an-analysis-of-disease-prevalence-drugs-in-development-regulatory-guidelines-and-market-opportunity-in-various-geographies
.
Table of Content
1. Executive Summary
2. Overview of NASH
2.1 Possible targets for the treatment of NASH
2.2 Drugs in the pipeline
2.3 Key Milestones
2.4 Drivers of M&A/ Licensing deals in NASH
2.5 NASH disease market opportunity to 2025
3. Products in Development and Competitive Landscape
3.1 Key Drugs/Companies Developing Drugs Against NASH
3.1.1 Obeticholic Acid – Intercept Pharmaceuticals/ Dainippon Sumitomo
3.1.2 Elafibranor – Genfit
3.1.3 Multiple programs – Gilead
3.1.4 Emricasan – Conatus Pharmaceuticals
3.1.5 Aramchol – Galmed Pharmaceuticals
3.1.6 Cenicriviroc – Tobira Therapeutics
3.1.7 IMM-124E – Immuron
3.1.8 GR-MD-02 – Galectin Therapeutics
3.1.9 TD139 - Galecto Biotech
3.1.10 SHP626 – Shire
3.1.11 PXS4728A – Boehringer Ingelheim
3.2 Repurposed Drugs for NASH
3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma
3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare
3.2.3 Victoza (liraglutide) - Novo Nordisk
4. NASH – Etiology, Pathogenesis, Diagnosis and Current Treatment
4.1 Cause, Symptoms, Pathogenesis, Diagnosis
4.2 Current treatment including Herbal Medicine
5. Regulatory Pathway
5.1 Challenges in trials using endpoints to define clinically meaningful benefits
5.2 Potential Clinical Trial Design for NASH and Endpoints
6. Annexure
2. Overview of NASH
2.1 Possible targets for the treatment of NASH
2.2 Drugs in the pipeline
2.3 Key Milestones
2.4 Drivers of M&A/ Licensing deals in NASH
2.5 NASH disease market opportunity to 2025
3. Products in Development and Competitive Landscape
3.1 Key Drugs/Companies Developing Drugs Against NASH
3.1.1 Obeticholic Acid – Intercept Pharmaceuticals/ Dainippon Sumitomo
3.1.2 Elafibranor – Genfit
3.1.3 Multiple programs – Gilead
3.1.4 Emricasan – Conatus Pharmaceuticals
3.1.5 Aramchol – Galmed Pharmaceuticals
3.1.6 Cenicriviroc – Tobira Therapeutics
3.1.7 IMM-124E – Immuron
3.1.8 GR-MD-02 – Galectin Therapeutics
3.1.9 TD139 - Galecto Biotech
3.1.10 SHP626 – Shire
3.1.11 PXS4728A – Boehringer Ingelheim
3.2 Repurposed Drugs for NASH
3.2.1 Remogliflozin etabonate - Islet Sciences/BHV pharma
3.2.2 Lipaglyn (saroglitazar) - Cadila Healthcare
3.2.3 Victoza (liraglutide) - Novo Nordisk
4. NASH – Etiology, Pathogenesis, Diagnosis and Current Treatment
4.1 Cause, Symptoms, Pathogenesis, Diagnosis
4.2 Current treatment including Herbal Medicine
5. Regulatory Pathway
5.1 Challenges in trials using endpoints to define clinically meaningful benefits
5.2 Potential Clinical Trial Design for NASH and Endpoints
6. Annexure
No comments:
Post a Comment